Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Sells $36,372.51 in Stock

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) Director Nancy A. Simonian sold 134,713 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The shares were sold at an average price of $0.27, for a total transaction of $36,372.51. Following the completion of the transaction, the director now directly owns 41,070 shares in the company, valued at approximately $11,088.90. The trade was a 76.64 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Syros Pharmaceuticals Price Performance

NASDAQ:SYRS opened at $0.27 on Friday. Syros Pharmaceuticals, Inc. has a 52 week low of $0.18 and a 52 week high of $8.17. The firm’s fifty day moving average is $1.72 and its 200-day moving average is $3.45. The company has a quick ratio of 2.25, a current ratio of 2.25 and a debt-to-equity ratio of 1.97.

Syros Pharmaceuticals (NASDAQ:SYRS) last released its quarterly earnings data on Thursday, October 31st. The company reported ($0.68) earnings per share for the quarter, topping the consensus estimate of ($0.76) by $0.08. During the same quarter last year, the company posted ($1.35) EPS. On average, equities analysts forecast that Syros Pharmaceuticals, Inc. will post -2.94 earnings per share for the current year.

Analyst Upgrades and Downgrades

SYRS has been the topic of a number of recent analyst reports. JMP Securities reissued a “market perform” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. Piper Sandler reiterated an “overweight” rating and issued a $5.00 price target (down from $13.00) on shares of Syros Pharmaceuticals in a research note on Tuesday, August 13th. TD Cowen reissued a “hold” rating on shares of Syros Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reaffirmed a “neutral” rating and set a $1.00 target price (down previously from $6.00) on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. Finally, Brookline Capital Management reaffirmed a “hold” rating on shares of Syros Pharmaceuticals in a report on Wednesday, November 13th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average target price of $3.33.

Institutional Trading of Syros Pharmaceuticals

Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Syros Pharmaceuticals by 21.3% during the first quarter. Vanguard Group Inc. now owns 928,046 shares of the company’s stock worth $4,965,000 after purchasing an additional 163,234 shares during the period. Opaleye Management Inc. boosted its position in shares of Syros Pharmaceuticals by 119.1% in the first quarter. Opaleye Management Inc. now owns 787,545 shares of the company’s stock valued at $4,213,000 after acquiring an additional 428,175 shares during the period. Kennedy Capital Management LLC bought a new stake in Syros Pharmaceuticals during the first quarter valued at approximately $2,166,000. Acadian Asset Management LLC lifted its position in Syros Pharmaceuticals by 101.5% during the second quarter. Acadian Asset Management LLC now owns 34,578 shares of the company’s stock valued at $178,000 after purchasing an additional 17,416 shares during the last quarter. Finally, Certuity LLC bought a new stake in Syros Pharmaceuticals during the second quarter valued at approximately $109,000. Hedge funds and other institutional investors own 91.47% of the company’s stock.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.